Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase

Journal of Biomedical Science

Volumn 17, Issue 1, 2010, Pages

  Wu, Gang ^a,b   Nan, Changlong ^b   Rollo, Johnathon C ^b   Huang, Xupei ^b   Tian, Jie ^a  

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; VALPROIC ACID; ANTICONVULSIVE AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TERATOGENIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FETUS; HEART DEVELOPMENT; HEART MUSCLE CELL; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOGENESIS; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS;

ANIMALS; ANTICONVULSANTS; FEMALE; HEART DEFECTS, CONGENITAL; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERATOGENS; VALPROIC ACID;

EID: 77949453165     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-17-16     Document Type: Article

References (29)

1. Valproate: a simple chemical with so much to offer. GM Peterson M Naunton, J Clin Pharm Ther 2005 30 417 421 10.1111/j.1365-2710.2005.00671.x 16164485
2. Oral valproic acid for epilepsy-long-term experience in therapy and side effects. T Gerstner N Bell S Konig, Expert Opin Pharmacother 2008 9 285 292 10.1517/14656566.9.2.285 18201150
3. Teratogenicity of sodium valproate. R Alsdorf DF Wyszynski, Expert Opin Drug Saf 2005 4 345 353 10.1517/14740338.4.2.345 15794725
4. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. C Kozma, Am J Med Genet 2001 98 168 175 10.1002/1096-8628(20010115)98:2<168::AID- AJMG1026>3.0.CO;2-O 11223853
5. Complex cardiac defect with hypoplastic right ventricle in a fetus with valproate exposure. K Ten Berg ACC van Oppen PGJ Nikkels ACG Groot GB van der Voet EH Brilstra D Lindhout, Prenatal Diagn 2005 25 156 158 10.1002/pd.1098 (Pubitemid 40327398)
6. Sodium valproate-induced cardiovascular abnormalities in the jcl:ICR mouse fetus: peak sensitivity of gestational day and dose-dependent effect. T Sonoda S Ohdo K Ohba T Okishima K Hayakawa, Teratology 1993 48 127 132 10.1002/tera.1420480206 8211818
7. Teratogenic effects of sodium valproate in mice and rats at midgestation and at term. E Menegola ML Broccia H Nau M Prati R Ricolfi E Giavini, Teratog Carcinog Mutagen 1996 16 97 108 10.1002/(SICI)1520-6866(1996)16:2<97::AID- TCM4>3.0.CO;2-A 8875740
8. Comparative effects of valproic acid sodium for Chiari-like malformation at 9 and 10 days of gestation in the rat. S Dura S Ceylan S Ceylan, Childs Nerv Syst 2001 17 399 404 10.1007/s003810000417 11465793
9. Effects of valproic acid on cardiac metabolism. T Daniels M Gallagher G Tremblay RL Rodgers, Can J Physiol Pharmacol 2004 82 927 933 10.1139/y04-096 15573154
10. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. M Gottlicher S Minucci P Zhu OH Kramer A Schimpf S Giavara JP Sleeman F Lo Coco C Nervi PG Pelicci T Heinzel, EMBO J 2001 20 6969 6978 10.1093/emboj/20.24.6969 11742974
11. Sodium valproate: an old drug with new roles. NN Nalivaeva ND Belyaev AJ Turner, Trends in Pharmacol Sci 2009 30 509 513 10.1016/j.tips.2009.07.002
12. Thyroid hormone inhibits slow skeletal TnI expression in cardiac TnI-null myocardial cells. B Riedel Y Jia J Du S Akerman XP Huang, Tissue & Cell 2005 37 47 51
13. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. KJ Livak TD Schmittgen, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609
14. Histone acetylation: a switch between repressive and permissive chromatin. A Eberharter PB Becker, EMBO Rep 2002 3 224 229 10.1093/embo-reports/ kvf053 11882541
15. Histone acetylation in chromatin structure and transcrition. M Grunstein, Nature 1997 389 349 352 10.1038/38664 9311776
16. Histone deacetylases: silencers for hire. HH Ng A Bird, Trends Biochem Sci 2000 25 121 126 10.1016/S0968-0004(00)01551-6 10694882
17. Acetylation and chromosomal functions. WL Cheung SD Briggs CD Allis, Curr Opin Cell Biol 2000 12 326 333 10.1016/S0955-0674(00)00096-X 10801466
18. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. SE Rundlett AA Carmen N Suka BM Turner M Grunstein, Nature 1998 392 831 835 10.1038/33952 9572144
19. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. MS Finnin JR Donigian A Cohen VM Richon RA Rifkind PA Marks R Breslow NP Pavletich, Nature 1999 401 188 195 10.1038/43710 10490031
20. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. JR Somoza RJ Skene BA Katz C Mol JD Ho BA Jennings C Luong A Arvai JJ Buggy E Chi J Tang B Sang E Verner R Wynands EM Leahy DR Dougan G Snell M Navre MW Knuth RV Swanson DE McRee LW Tari, Structure 2004 12 1325 1334 10.1016/j.str.2004.04.012 15242608
21. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. A Vannini C Volpari G Filocamo EC Casavola M Brunetti D Renzoni P Chakravarty C Paolini R Francesco P Gallinari C Steinkuhler S Di Marco, Proc Natl Acad Sci USA 2004 101 15064 15069 10.1073/pnas.0404603101 15477595
22. Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Y Sakata CN Kamei H Nakagami R Bronson JK Liao MT Chin, Proc Natl Acad Sci USA 2002 99 16197 16202 10.1073/pnas.252648999 12454287
23. The spectrum of cardiovascular anomalies in CHF1/Hey2 deficient mice reveals roles in endocardial cushion, myocardial and vascular maturation. Y Sakata N Koibuchi F Xiang JM Youngblood CN Kamei MT Chin, J Mol Cell Cardiol 2006 40 267 273 10.1016/j.yjmcc.2005.09.006 16242143
24. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Q Lin J Schwarz C Bucana EN Olson, Science 1997 276 1404 1407 10.1126/science.276.5317.1404 9162005
25. MEF2 activates a genetic program promoting chamber dilation and contractile dysfunction in calcineurin-induced heart failure. RJ van Oort E van Rooij M Bourajjaj J Schimmel MA Jansen R van der Nagel PA Doevendans MD Schneider CJA van Echteld LJ De Windt, Circulation 2006 114 298 308 10.1161/CIRCULATIONAHA.105.608968 16847152
26. Mutations in human TBX5 cause limb and cardiac malformation in Holt-Oram syndrome. CT Basson DR Bachinsky RC Lin T Levi JA Elkins J Soults D Grayzel E Kroumpouzou TA Traill J Leblanc-Straceski B Renault R Kucherlapati JG Seidman CE Seidman, Nat Genet 1997 15 30 35 10.1038/ng0197-30 8988165
27. Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. QY Li RA Newbury-Ecob JA Terrett DI Wilson AR Curtis GH Yi T Gebuhr PJ Bullen SC Robson T Strachan D Bonnet S Lyonnet ID Young JA Raeburn AJ Buckler DJ Law JD Brook, Nat Genet 1997 15 21 29 10.1038/ng0197-21 8988164
28. Chamber-specific cardiac expression of Tbx5 and heart defects in Holt-Oram syndrome. BG Bruneau M Logan N Davis T Levi CJ Tabin JG Seidman CE Seidman, Developmental Biol 1999 211 100 108 10.1006/dbio.1999.9298 (Pubitemid 29315824)
29. Ventricular expression of tbx5 inhibits normal heart chamber development. CM Liberatore RD Searcy-Schrick KE Yutzey, Developmental Biol 2000 223 169 180 10.1006/dbio.2000.9748 (Pubitemid 30439527)